Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3950177 | 0.99 | CA1 (0.54) | CA1CA2HSD17B2MEN1CYP1A2 | |
| SCHEMBL3276784 | 0.88 | MEN1 (0.54) | CA1CA2HSD17B2MEN1CYP1A2 | |
| SCHEMBL3947875 | 0.88 | MEN1 (0.51) | MEN1CYP1A2CYP2C19KMT2ANR1H4 | |
| Hydrochloric Acid SCHEMBL4158004 | 0.87 | MEN1 (0.53) | CA1CA2HSD17B2MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3944192 | 0.87 | MEN1 (0.50) | MEN1CYP1A2CYP2C19KMT2ANR1H4 | |
| SCHEMBL5175538 | 0.87 | ERCC1 (0.54) | HSD17B2MEN1KMT2ANR1H4 | |
| SCHEMBL4162394 | 0.86 | PYGL (0.59) | MEN1CYP1A2CYP2C19KMT2ANR1H4 | |
| SCHEMBL3272732 | 0.86 | P2RX7 (0.57) | MEN1CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL4161717 | 0.85 | PYGL (0.58) | MEN1CYP1A2CYP2C19KMT2ANR1H4 | |
| SCHEMBL13683247 | 0.85 | TSHR (0.65) | CA1CA2HSD17B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | claimed |
| US-7691876-B2 | Heterobicyclic amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | claimed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | claimed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | claimed |
| EP-1984364-A1 | HETEROBICYCLIC AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | claimed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | claimed |
| WO-2007090751-A1 | HETEROBICYCLIC AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | claimed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | claimed |
| EP-1984322-B1 | BENZAMIDE AND HETEROARENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-7691876-B2 | Heterobicyclic amide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2007090751-A1 | HETEROBICYCLIC AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | CA1 4376/4885CA2 2610/4885HSD17B2 543/4885 |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | CA1 4644/4885CA2 4559/4885HSD17B2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.